RxDoctor Payments Data

Brian Weiford, MD

Cardiovascular Disease · Kansas City, KSNPI 1144242538

Payments from drug & device makers

$977in general payments, 2019–2025

Across 28 payments — averaging $34.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$432
  • Boston Scientific$231
  • Amgen$94
  • Novo Nordisk$56
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$53
  • Merck$46
  • plus $65 from 3 others

What the payments were for

  • Food & beverage$977100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$977 in reported general payments places this provider in the 30th percentile of 175 cardiovascular disease providers in Kansas.

See all cardiovascular disease providers in Kansas

Medicare billing

Part B allowed, 2024
$109,505
Medicare patients
1,104
Services billed
2,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban296$324,989
Repatha SureclickEvolocumab245$196,216
EntrestoSacubitril/Valsartan58$78,300
XareltoRivaroxaban82$77,414
Praluent PenAlirocumab60$44,037
JardianceEmpagliflozin37$39,863
MultaqDronedarone Hcl24$39,698
FarxigaDapagliflozin Propanediol28$31,637
Icosapent Ethyl21$8,143
Ezetimibe236$5,436
Rosuvastatin Calcium441$5,379
Atorvastatin Calcium431$3,725
Dabigatran EtexilateDabigatran Etexilate Mesylate15$3,648
Potassium Chloride117$3,474
Metoprolol Succinate270$3,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$324,989296 claims
Sanofi-aventis U.S. LLCMultaq$39$39,69824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 175 cardiovascular disease providers in Kansas.

Other cardiovascular disease in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →